Cellular and T cell engager Immunotherapy
Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma
Sridevi Rajeeve, MD
Hematology & Medical Oncology Fellow
Icahn School of Medicine at Mount Sinai
New York, New York, United States